January 18, 2022
2 min watch
Save
VIDEO: Intracameral bimatoprost implant helps reduce glaucoma medication burden
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
WAIKOLOA, Hawaii — At Hawaiian Eye 2022, I. Paul Singh, MD, discusses some of the advantages of the use of Durysta intracameral bimatoprost injection to lower IOP in patients with glaucoma.
“What’s interesting about Durysta now, having about a year and a half experience with it is that although it releases bimatoprost for 4 months, the duration of effect in some patients can be 6 months, 9 months, even up to a couple of years.”
Published by:
Sources/Disclosures
Collapse
Source:
I. Paul Singh, MD
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.